Feature Article | Leen Kawas on Equity by Design: How Innovation Can – and Should – Close Gaps in Global Healthcare
- chance51029
- Oct 16
- 1 min read
Leen Kawas, Managing General Partner at Propel Bio Partners, is reshaping biotech investing through a strategy grounded in health equity and inclusive innovation. In response to the stark disparities in clinical trial representation, treatment access, and affordability, Kawas advocates for intentional innovation—backing companies that prioritize underserved populations globally.
From Persephone Biosciences’ microbiome research for infant health to Inherent Biosciences’ epigenetic diagnostics for male infertility and OmniVis’s affordable cholera testing in vulnerable regions, her portfolio reflects a patient-centric ethos. Kawas believes closing healthcare gaps isn’t just a moral imperative—it’s a strategic advantage, unlocking new markets and improving therapeutic outcomes.
With healthcare costs rising and inequality growing, Kawas positions Propel Bio Partners at the forefront of inclusive biotech, showing how capital aligned with impact delivers stronger returns and greater societal value.